OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 01:53 UTC. Every row links to its source record.

FBN2 fibrillin 2

ENSG00000138829 · protein coding · Open Targets profile

[Fibrillin-2]: Fibrillins are structural components of 10-12 nm extracellular calcium-binding microfibrils, which occur either in association with elastin or in elastin-free bundles. Fibrillin-2- containing microfibrils regulate the early process of elastic fiber assembly. Regulates osteoblast maturation by controlling TGF-beta bioavailability and calibrating TGF-beta and BMP levels, respectively. .

In 3 of 4 cancers, the evidence for FBN2 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751neuroblastomaneuroblastomaneuroblastoma: somatic 0.61ovarian neoplasmovarian neoplasmovarian neoplasm: germline 0.49Familial prostate cancerFamilial prostate cancerFamilial prostate cancer: somatic 0.18prostate cancerprostate cancerprostate cancer: somatic 0.18

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Antibody
UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
PROTAC
Database Ubiquitination

gnomAD loss of function constraint: o/e 0.2953000068664551 (upper bound 0.3472900092601776). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of FBN2's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of FBN2's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.